Spironolactone-furosemide combination therapy and acid-base disorders in liver cirrhosis patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410742" target="_blank" >RIV/00216208:11130/20:10410742 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/20:10410742 RIV/00023001:_____/20:00079637

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F7u3wW2B_M" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F7u3wW2B_M</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5414/CP203624" target="_blank" >10.5414/CP203624</a>

Result language

angličtina

Original language name

Spironolactone-furosemide combination therapy and acid-base disorders in liver cirrhosis patients

Original language description

Objective: Respiratory alkalosis (RA) and dilutional hyperchloremic acidosis (DHA) are the most common acid-base balance (ABB) disorders in patients with liver cirrhosis. The aims of this study were to clarify whether RA develops in relation to DHA via respiratory compensation of metabolic acidosis and whether spironolactone in combination with low-dose furosemide - diuretics known to ameliorate DHA - positively affects RA in liver cirrhosis patients. Materials and methods: 59 patients with advanced cirrhosis were divided into two groups. Group D consisted of individuals (urine sodium concentration (UNa+) &gt; 20 mmol/L) who responded to combination therapy consisting of spironolactone and low-dose furosemide. The non-D group consisted of individuals (UNa+ &lt;= 20 mmol/L) who either did not respond to the treatment or who were not administered it. In both groups, we examined serum and urine concentrations of electrolytes and ABB parameters, including S-Na(+)-SCl- and S-Na(+)/SCl- values. Results: In group D, we found a statistically significant relationship between pCO(2) and SHCO3-: r = 0.756 (p &lt; 0.001) and between pCO(2) and SNa+-SCl-: r = 0.522 (p = 0.001). Neither Salb nor the corrected anion gap were associated with changes in SHCO3- or pCO(2) values. Although SHCO3- values were normal, abnormal pCO(2) values were observed in one third of group D patients. Based on multivariable analysis, SHCO3- proved to be a statistically significant influencing factor on pCO(2) values. Conclusion: DHA contributes to the development of RA in individuals with liver cirrhosis. Reducing DHA by means of effective diuretic therapy comprising spironolactone and furosemide has a beneficial effect on RA in such patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Clinical Pharmacology and Therapeutics

ISSN

0946-1965

e-ISSN

—

Volume of the periodical

58

Issue of the periodical within the volume

5

Country of publishing house

DE - GERMANY

Number of pages

7

Pages from-to

261-267

UT code for WoS article

000527343300003

EID of the result in the Scopus database

2-s2.0-85084167582